8-substituted benzoazepines as toll-like receptor modulators
Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in the treatment of autoimmunity, inflammation allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency.
1. A compound of the Formula
and tautomers, and pharmaceutically acceptable salts thereof, wherein:
Y is an aryl or heteroaryl ring, wherein said aryl and heteroaryl rings are substituted with one or more groups independently selected from alkenyl, alkynyl, Br, CN, OH, NR 6 R 7 , C(═O)R 8 , NR 6 SO 2 R 7 , (C 1 -C 6 alkyl)amino, R 6 OC(═O)CH═CH 2 —, SR 6 and SO 2 R 6 , and wherein said aryl and heteroaryl rings are optionally further substituted with one or more groups independently selected from F, Cl, CF 3 , CF 3 O—, HCF 2 O—, alkyl, heteroalkyl and ArO—;
R 1 , R 3 and R 4 are independently selected from H, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl, wherein said alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more groups independently selected from alkyl, alkenyl, alkynyl, F, Cl, Br, I, CN, OR 6 , NR 6 R 7 , C(═O)R 6 , C(═O)OR 6 , OC(═O)R 6 , C(═O)NR 6 R 7 , (C 1 -C 6 alkyl)amino, CH 3 OCH 2 O—, R 6 OC(═O)CH═CH 2 —, NR 6 SO 2 R 7 , SR 6 and SO 2 R 6 ,
or R 3 and R 4 together with the atom to which they are attached form a saturated or partially unsaturated carbocyclic ring, wherein said carbocyclic ring is optionally substituted with one or more groups independently selected from alkyl, alkenyl, alkynyl, F, Cl, Br, I, CN, OR 6 , NR 6 R 7 , C(═O)R 6 , C(═O)OR 6 , OC(═O)R 6 , C(═O)NR 6 R 7 , (C 1 -C 6 alkyl)amino, CH 3 OCH 2 O—, R 6 OC(═O)CH═CH 2 —, NR 6 SO 2 R 7 , SR 6 and SO 2 R 6 ;
R 2 and R 8 are independently selected from H, OR 6 , NR 6 R 7 , alkyl, alkenyl, alkynyl,heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl, wherein said alkyl,alkenyl, alkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more groups independently selected from alkyl, alkenyl,alkynyl, F, Cl, Br, I, CN, OR 6 , NR 6 R 7 , C(═O)R 6 , C(═O)OR 6 , OC(═O)R 6 , C(═O)NR 6 R 7 , (C 1 -C 6 alkyl)amino, CH 3 OCH 2 O—, R 6 OC(═O)CH═CH 2 —, NR 6 SO 2 R 7 , SR 6 and SO 2 R 6 ;
R 5a , R 5b , and R 5c are independently H, F, Cl, Br, I, OMe, CH 3 , CH 2 F, CHF 2 or CF 3 ; and
R 6 and R 7 are independently selected from H, alkyl,or heteroalkyl.
2. The compound of claim 1 , wherein R 2 is OR 6 .
3. The compound of claim 2 , wherein R 6 is alkyl.
4. The compound of claim 3 , wherein R 6 is ethyl.
5. The compound of claim 1 , wherein R 2 is NR 6 R 7 .
6. The compound of claim 1 , wherein R 6 and R 7 are independently H, ethyl, propyl, or CH 2 CH 2 OCH 3 .
7. The compound of claim 1 , wherein Y is aryl.
8. The compound of claim 7 , wherein said aryl is substituted with C(═O)R 8 .
9. The compound of claim 8 , wherein R 8 is OR 6 , NR 6 R 7 or heterocycloalkyl.
10. The compound of claim 9 , wherein R 6 and R 7 are independently selected from H and alkyl.
11. The compound of claim 9 , wherein Y is
12. The compound of claim 1 , wherein R 1 , R 3 , R 4 , R 5a , R 5b and R 5c are each hydrogen.
13. The compound of claim 1 , selected from:
(1E,4E)-ethyl 2-amino-8-(pyrrolidine-1carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxylate;
(1E,4E)-ethyl 2-amino-8-(4-(methoxycarbonyl)phenyl)-3H-benzo[b]azepine-4-carboxylate;
(1E,4E)-ethyl 2-amino-8-(4-(methylcarbamoyl)phenyl)-3H-benzo[b]azepine-4-carboxylate;
(1E,4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxamide; and
pharmaceutically acceptable salts thereof.
14. A pharmaceutical composition, which comprises a compound as claimed in claim 1 together with a pharmaceutically acceptable diluent or carrier.
15. The compound
(1E,4E)-ethyl 2-amino-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxylate; and pharmaceutically acceptable salts thereof.
16. The compound
(1E,4E)-ethyl 2-amino-8-(4-(methoxycarbonyl)phenyl)-3H-benzo[b]azepine-4-carboxylate; and pharmaceutically acceptable salts thereof.
17. The compound
(1E,4E)-ethyl 2-amino-8-(4-(methylcarbamoyl)phenyl)-3H-benzo[b]azepine-4-carboxylate; and pharmaceutically acceptable salts thereof.
18. The compound of
(1E,4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxamide; and pharmaceutically acceptable salts thereof.
19. A pharmaceutical composition, which comprises a compound as claimed in claim 15 together with a pharmaceutically acceptable diluent or carrier.
20. A pharmaceutical composition, which comprises a compound as claimed in claim 16 together with a pharmaceutically acceptable diluent or carrier.
21. A pharmaceutical composition, which comprises a compound as claimed in claim 17 together with a pharmaceutically acceptable diluent or carrier.
22. A pharmaceutical composition, which comprises a compound as claimed in claim 18 together with a pharmaceutically acceptable diluent or carrier.